ASND ascendispharma.com Earnings growth forecast for next year
Ascendis Pharma A/S relies on manufacturing outsourcing, minimizing its own production facilities. The forward-looking net income per share growth forecast demonstrates consolidation, where the -37.30 level serves as a critical mark. Slow-release molecule technology protects revenues from competition, while Skytrofa sales drive current financial results and support market expectations.
ASND (ascendispharma.com): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Ascendis Pharma A/S|ASND - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ascendis Pharma|ASND - Company Total Debt Obligations|Debt to Book Capitalization Ratio Ascendis Pharma|ASND - Company Long-Term Liabilities|Company Short-Term Debts Ascendis Pharma|Quick Liquidity ascendispharma.com
- net income and valuation ratios data:
ASND - Net Financial Result|Projected Future Earnings Ascendis Pharma A/S|ASND - Price to Earnings Ratio|Forward P/E Multiple Ascendis Pharma A/S|ASND - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma|ASND - Operating profit before amortization|Net earnings per share (EPS TTM) Ascendis Pharma|ASND - Earnings per share for the last 12 months|Quarterly EPS earnings growth ascendispharma.com|ASND - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Ascendis Pharma A/S
Initial company analysis:ASND, Ascendis Pharma Inc.
The indicator is calculated as the percentage change in expected net earnings per share for the next fiscal period relative to the current one. This metric assesses the business's ability to generate additional income amid macroeconomic volatility. For Ascendis Pharma A/S (ASND), earnings growth is driven by the monetization of the TransCon platform, which fosters high patient loyalty to long-acting drugs. The dynamics of these expectations are reflected in the projected growth of net earnings per share for period n+1.
Analysis of competing companies
MDGL (Madrigal Pharma) - Earnings growth forecast for next year|Earnings growth forecast for next year Corcept Therapeutics Corp|Earnings growth forecast for next year RYTM|Net earnings per share growth forecast for next year AKRO (akerotx.com)|Net earnings per share growth forecast for next year Metsera MTSR|MoonLake Immunotherapeutics AG (MLTX) - Expected net earnings per share growth next year|CRNX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio|Agios (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Structure Pharma (GPCR)|Expected earnings per share growth for next year MiMedx Corp MDXG|Earnings growth forecast for next year RZLT (Rezolute, Inc.)|Earnings growth forecast for next year lexpharma.com LXRX|MBX - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Altimmune Inc ALT|AARD: Earnings growth forecast for next year|Expected earnings per share growth for next year Sagimet Biosciences Inc|BIOA (BioAge Labs, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year biomeafusion.com BMEA|Net earnings per share growth forecast for next year Quince Therapeutics (QNCX)|Fractyl Health Inc. - Projected earnings per share growth rate for next year|Earnings growth forecast for next year VTVT (vTv Therapeutics)|ATPC: Projected earnings per share growth rate for next year|Pluri Inc - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Synlogic, Inc. SYBX|Lipocine (LPCN) - Net earnings per share growth forecast for next year|MTNB - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year SPRB|GLTO: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Carmell Corporation (CTCX)|LUMO: Net earnings per share change forecast for next year|Earnings growth forecast for next year ONVO (Organovo)|Expected earnings per share trend next year RDUS
